Skip to content

Physician-led care since 20194.9 on Google

Text (407) 233-4006Call

Not sure where to start? Answer a few questions about your symptoms in the 4-minute hormone quiz.

Take the quiz

Not near a clinic? Peptide therapy is available by telehealth in 27 states.Telehealth

Your care team

  • Dr. Joseph Clark, D.O.

    Dr. Joseph Clark, D.O.

    Chief Medical Officer

    Board certified in Emergency Medicine, with 20+ years in medicine.

  • Tomo Marjanovic

    Tomo Marjanovic

    Founder and CEO

    Former police officer awarded the Medal of Valor. IFAH Top 100 Healthcare Visionary.

4.9 on Google from 700+ reviews

Aspire Rejuvenation Clinic

Menu

Text or call us at (407) 233-4006. Mon to Fri, 9:30 AM to 6:00 PM.

Book a Consultation

Peptide Therapy  /  SS-31 (Elamipretide)

SS-31 (Elamipretide)

SS-31, also known as elamipretide or Bendavia, is a mitochondrial-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. It stabilizes cardiolipin, a phospholipid essential for electron transport chain efficiency, and has been studied in multiple Phase 3 clinical trials for mitochondrial dysfunction.

ClassificationSynthetic Tetrapeptide (Mitochondrial-Targeted)
Sequence Length4 Amino Acids
Primary InterestMitochondrial Function & Cellular Energy
Research StatusPhase 3 Clinical Trials
Interested in SS-31 (Elamipretide)?

Talk with an Aspire clinician about whether SS-31 (Elamipretide) may be appropriate for your health goals.

Text Us Now
(407) 233-4006
What is SS-31?

Elamipretide - Mitochondrial Cardiolipin Stabilizer

SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2), also known as elamipretide or Bendavia, is a synthetic tetrapeptide with a unique property: it carries a net positive charge that drives it to concentrate in the inner mitochondrial membrane at concentrations 1,000-5,000 times higher than in the cytoplasm. Once there, it binds to cardiolipin, a phospholipid that is essential for the structural organization and function of the electron transport chain complexes.

Elamipretide has advanced further through clinical trials than most peptides in the longevity and cellular health space. It has been studied in Phase 2 and Phase 3 trials for primary mitochondrial myopathy (Barth syndrome), heart failure, age-related macular degeneration, and renal function. While it has not yet received FDA approval, the depth of clinical investigation distinguishes it from many compounds in the peptide therapy space. Research focuses on its ability to restore mitochondrial efficiency in conditions where mitochondrial dysfunction is a primary driver of disease.

Aspire offers SS-31 (elamipretide) through licensed U.S. 503A compounding pharmacies. Given its clinical research profile, treatment is prescribed by Aspire clinicians with appropriate evaluation and monitoring, with particular attention to patients with concerns related to mitochondrial function, energy production, and age-related cellular decline.

Lifestyle photography representing healthy aging energy vitality - SS-31 therapy at Aspire Rejuvenation
How It Works

Proposed Mechanism of Action

1
Subcutaneous Injection
SS-31 is administered via subcutaneous injection and rapidly distributes to mitochondria-rich tissues throughout the body
2
Mitochondrial Concentration
The peptide's positive charge drives it to accumulate in the inner mitochondrial membrane at 1,000-5,000x cytoplasmic concentrations
3
Cardiolipin Stabilization
SS-31 binds to and stabilizes cardiolipin, restoring the structural organization of electron transport chain complexes I, III, and IV
4
ETC Efficiency Restoration
Stabilized cardiolipin improves electron transfer efficiency, reduces electron leak and ROS production, and restores ATP synthesis capacity

Cardiolipin is a unique phospholipid found exclusively in the inner mitochondrial membrane. It is essential for the proper assembly and function of electron transport chain (ETC) complexes and the ATP synthase supercomplex. As cardiolipin becomes oxidized or depleted with age and disease, ETC complexes destabilize, electron transfer becomes inefficient, reactive oxygen species (ROS) production increases, and ATP synthesis declines. This creates a vicious cycle where mitochondrial dysfunction produces more oxidative damage, which further damages mitochondria.

SS-31 breaks this cycle by binding to cardiolipin and restoring its structural role in organizing ETC complexes. Research has shown that SS-31 reduces electron leak at Complex I and Complex III, decreases mitochondrial ROS production, improves the efficiency of ATP synthesis, and restores mitochondrial membrane potential. Unlike antioxidants that scavenge ROS after they are produced, SS-31 addresses the upstream structural problem that causes excess ROS production in the first place, making it a fundamentally different approach to mitochondrial health.

Areas of Interest

What SS-31 (Elamipretide) Is Being Explored For

These are the primary areas where SS-31 (Elamipretide) has been studied or discussed in the context of peptide therapy. Research depth varies by area.

Mitochondrial Dysfunction
The primary area of research. SS-31 has been studied in Phase 3 trials for primary mitochondrial myopathy, including Barth syndrome, where cardiolipin deficiency is the direct cause of disease. Its mechanism is relevant to any condition driven by impaired mitochondrial function.
Cardiac Function
The heart is the most mitochondria-dense organ in the body. SS-31 (as Bendavia) has been studied in clinical trials for heart failure and cardiac ischemia-reperfusion injury, where mitochondrial dysfunction contributes to impaired cardiac output and tissue damage.
Age-Related Cellular Decline
Mitochondrial dysfunction is considered a hallmark of aging. SS-31 is explored for its potential to address the progressive decline in mitochondrial efficiency that underlies fatigue, reduced exercise capacity, and cellular aging in otherwise healthy aging populations.
Renal & Ophthalmic Health
Clinical trials have investigated SS-31 for age-related macular degeneration and renal function, conditions in which the high metabolic demands of retinal and kidney tissues make them particularly vulnerable to mitochondrial dysfunction.
Available at Aspire

How SS-31 (Elamipretide) Is Offered

SS-31 (Elamipretide) is available through Aspire in the following formulations, all compounded by licensed U.S. 503A pharmacies. Your clinician will recommend the appropriate form based on your goals and treatment plan.

Injectable (Subcutaneous)
Questions About SS-31 (Elamipretide)?

Text our team anytime during business hours.
Monday through Friday, 9:30 AM - 6:00 PM.
We're here to help you understand your options.

Text Us Now — (407) 233-4006
The Aspire Approach

How Treatment Works

Peptide therapy at Aspire follows a clinician-guided process. SS-31 (Elamipretide) is not available for self-prescribing or anonymous purchase.

1
Conversation
Text or call Aspire. Discuss your energy, mitochondrial health, or cellular aging concerns and whether SS-31 may be relevant to your goals.
2
Evaluation
Clinical assessment including medical history, energy and fatigue patterns, current medications, and evaluation of conditions that may involve mitochondrial dysfunction.
3
Treatment
If appropriate, your clinician prescribes SS-31 compounded through a licensed 503A pharmacy with a protocol tailored to your specific health goals.
4
Monitoring
Ongoing follow-up to assess energy response, functional capacity, and any side effects. Lab monitoring as clinically indicated to track relevant biomarkers.
Frequently Asked Questions

SS-31 (Elamipretide) FAQ

SS-31 is fundamentally different from antioxidant supplements like CoQ10 or MitoQ. Rather than scavenging reactive oxygen species after they are produced, SS-31 addresses the structural cause of excess ROS production by stabilizing cardiolipin in the inner mitochondrial membrane. It targets the upstream problem rather than the downstream symptom.
Yes. SS-31 (elamipretide) has been studied in multiple Phase 2 and Phase 3 human clinical trials for Barth syndrome, heart failure, age-related macular degeneration, and renal function. It has received FDA Fast Track designation for Barth syndrome. This level of clinical investigation is unusual for a compounded peptide.
In clinical trials, the most commonly reported side effects include injection-site reactions and occasional mild gastrointestinal effects. The compound has generally been well-tolerated across multiple clinical trials. Your clinician will discuss the safety data during evaluation.
SS-31 is most commonly explored by patients with concerns related to mitochondrial function, including age-related energy decline, exercise intolerance, and conditions associated with mitochondrial dysfunction. Your clinician will evaluate whether your specific situation aligns with SS-31's mechanism of action.
Preclinical and clinical research has investigated SS-31's effects on exercise tolerance and capacity, particularly in populations with impaired mitochondrial function. By improving mitochondrial efficiency and ATP production, it may support improved exercise capacity. Results vary by individual and underlying condition.
Mitochondrial dysfunction is recognized as a hallmark of biological aging. Cardiolipin oxidation and depletion accelerate with age, contributing to declining energy production, increased oxidative damage, and cellular senescence. SS-31's ability to stabilize cardiolipin and restore mitochondrial function is why it is studied in the context of aging biology.
SS-31 (elamipretide) is not yet FDA approved. It has received FDA Fast Track designation for Barth syndrome and has been studied in multiple Phase 2 and Phase 3 clinical trials. It is available through licensed 503A compounding pharmacies pursuant to individual prescriptions.
SS-31 and NAD+ address different aspects of mitochondrial function and are often discussed as complementary. SS-31 stabilizes the structural organization of electron transport chain complexes, while NAD+ provides the essential electron carrier for energy production. Your clinician will evaluate whether combining them is appropriate for your situation.

SS-31/elamipretide has one of the most advanced clinical research profiles in the peptide space, with multiple Phase 2 and Phase 3 trials completed or ongoing. While it has not yet received FDA approval, it has received Fast Track designation from the FDA for Barth syndrome. The clinical trial data provides a more robust evidence base than is available for most compounded peptides.

Ready to explore SS-31 (Elamipretide)?

Talk with an Aspire clinician about your goals and whether SS-31 (Elamipretide) therapy may be appropriate for you.

Text Us Now
(407) 233-4006  ·  8014 Via Dellagio Way #104, Orlando, FL 32819
ASPIRE CLINIC LOCATIONS

Speak With Our Experts